COMPENDIUM ON FUNCTIONAL MEDICINE - Flipbook - Page 901
[68] Pearson, T. A., Mensah, G. A., Alexander, R. W., et al. (2003).
Markers of inflammation and cardiovascular disease: application
to clinical and public health practice: a statement for healthcare
professionals from the Centers for Disease Control and Prevention
and the American Heart Association. Circulation, 107(3), 499-511.
[69] Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000).
C-reactive protein and other markers of inflammation in the
prediction of cardiovascular disease in women. New England
Journal of Medicine, 342(12), 836-843.
[70] Cesari, M., Penninx, B. W., Newman, A. B., et al. (2003).
Inflammatory markers and onset of cardiovascular events: results
from the Health ABC study. Circulation, 108(19), 2317-2322.
[71] Kushner, I., Rzewnicki, D., & Samols, D. (2006). What does minor
elevation of C-reactive protein signify? American Journal of
Medicine, 119(2), 166.e17-28.
[72] Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., &
Hennekens, C. H. (1997). Inflammation, aspirin, and the risk of
cardiovascular disease in apparently healthy men. New England
Journal of Medicine, 336(14), 973-979.
[73] Sokolove, J., Brennan, M. J., Sharpe, O., et al. (2013).
Citrullination within the atherosclerotic plaque: a potential target
for the anti-citrullinated protein antibody response in rheumatoid
arthritis. Arthritis & Rheumatism, 65(7), 1719-1724.
[74] Fasano, A. (2012). Leaky gut and autoimmune diseases.
Clinical Reviews in Allergy & Immunology, 42(1), 71-78.
[75] Yudkin, J. S., Stehouwer, C. D., Emeis, J. J., & Coppack, S. W.
(1999). C-reactive protein in healthy subjects: associations with
obesity, insulin resistance, and endothelial dysfunction: a potential
role for cytokines originating from adipose tissue? Arteriosclerosis,
Thrombosis, and Vascular Biology, 19(4), 972-978.
901
